Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) lost 0.5% and 0.9% ...
After reinvigorating a decades-old schizophrenia drug in an innovative long-acting treatment option, Teva is looking to unlock its next chapter of mental health treatment. TEV’749 is a long ...
Below is Validea's guru fundamental report for TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR) (TEVA). Of the 22 guru strategies we follow, TEVA rates highest using our Twin Momentum Investor model based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback